Barclays Upgrades Chemours (NYSE:CC) to Hold

Chemours (NYSE:CC) was upgraded by Barclays to a “hold” rating in a report released on Monday, Zacks reports.

Several other equities research analysts have also commented on CC. Morgan Stanley set a $18.00 price objective on shares of Chemours in a research report on Monday, August 10th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. UBS Group dropped their target price on shares of Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, October 5th. JPMorgan Chase & Co. cut their target price on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Finally, Mizuho reaffirmed a “neutral” rating and issued a $15.00 price target (down from $18.00) on shares of Chemours in a report on Wednesday. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Chemours currently has an average rating of “Hold” and an average target price of $18.09.

Chemours Stock Down 2.9%

CC opened at $12.81 on Monday. The business’s fifty day moving average is $14.79 and its two-hundred day moving average is $18.97. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41. Chemours has a one year low of $10.44 and a one year high of $28.67.

Chemours (NYSE:CC) last posted its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the company posted ($2.54) EPS. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. Analysts anticipate that Chemours will post 0.84 EPS for the current fiscal year.

Insider Transactions at Chemours

In other news, insider Calderon Gerardo Familiar purchased 1,935 shares of the stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the acquisition, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Denise Dignam acquired 3,378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was purchased at an average cost of $14.95 per share, with a total value of $50,501.10. Following the transaction, the chief executive officer owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 8,663 shares of company stock worth $130,601 over the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Institutional Trading of Chemours

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Chemours during the second quarter worth approximately $477,769,000. Wolf Hill Capital Management LP purchased a new stake in shares of Chemours during the 2nd quarter valued at $59,698,056. Bank of New York Mellon Corp purchased a new stake in shares of Chemours during the 2nd quarter valued at $33,353,000. Legal & General Group Plc purchased a new stake in shares of Chemours during the 2nd quarter valued at $28,400,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Chemours during the 2nd quarter worth $18,119,000. 76.26% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.